| Dr Jamar A Melton, MD | |
|
7373 Perkins Rd, Baton Rouge, LA 70808-4326 | |
| (225) 769-4044 | |
| Not Available |
| Full Name | Dr Jamar A Melton |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 7373 Perkins Rd, Baton Rouge, Louisiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659419190 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 13493R (Louisiana) | Primary |
| Entity Name | Baton Rouge Clinic, A Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871546911 PECOS PAC ID: 1254317001 Enrollment ID: O20040624000911 |
News Archive
During the past 30 years, the number of patients with cancers that originate near the junction of the esophagus and stomach has increased approximately 600 percent in the United States. The first extensive probe of the DNA of these esophageal adenocarcinomas has revealed that many share a distinctive mix-up of letters of the genetic code, and found more than 20 mutated genes that had not previously been linked to the disease.
Allos Therapeutics, Inc. today announced topline results from the Company's randomized Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) who had received one or two prior systemic treatments including at least one prior platinum-based regimen. The objective of the trial was to estimate the efficacy of FOLOTYN compared to that of erlotinib as assessed by overall survival.
In a paper published online in the journal Nature, a team of deCODE scientists detail a major mechanism through which genetic factors contribute to major public health problems.
The Washington Post reports that enforcing the requirement that almost all Americans have health insurance represents the biggest boost in the agency's responsibilities in decades.
Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jamar A Melton, MD 7373 Perkins Rd, Baton Rouge, LA 70808-4326 Ph: (225) 769-4044 | Dr Jamar A Melton, MD 7373 Perkins Rd, Baton Rouge, LA 70808-4326 Ph: (225) 769-4044 |
News Archive
During the past 30 years, the number of patients with cancers that originate near the junction of the esophagus and stomach has increased approximately 600 percent in the United States. The first extensive probe of the DNA of these esophageal adenocarcinomas has revealed that many share a distinctive mix-up of letters of the genetic code, and found more than 20 mutated genes that had not previously been linked to the disease.
Allos Therapeutics, Inc. today announced topline results from the Company's randomized Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) who had received one or two prior systemic treatments including at least one prior platinum-based regimen. The objective of the trial was to estimate the efficacy of FOLOTYN compared to that of erlotinib as assessed by overall survival.
In a paper published online in the journal Nature, a team of deCODE scientists detail a major mechanism through which genetic factors contribute to major public health problems.
The Washington Post reports that enforcing the requirement that almost all Americans have health insurance represents the biggest boost in the agency's responsibilities in decades.
Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A.
› Verified 9 days ago
Manish Gope Raisingani, Pediatrics Medicare: Medicare Enrolled Practice Location: 8200 Constantin Blvd Fl 4, Baton Rouge, LA 70809 Phone: 225-765-5500 Fax: 225-765-1733 | |
Dr. Daniel Gregg Sloven, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 8200 Constantin Blvd Fl 4, Baton Rouge, LA 70809 Phone: 225-765-5500 Fax: 225-765-2054 | |
Traci T. Lacy, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 7373 Perkins Rd, Baton Rouge, LA 70808 Phone: 225-769-4044 | |
Dr. Michelle L Flechas, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 12525 Perkins Rd, Suite C, Baton Rouge, LA 70810 Phone: 225-769-2003 Fax: 225-767-3055 | |
Dr. Richard Francis Lasseigne Jr., MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 8300 Constantin Blvd, Baton Rouge, LA 70809 Phone: 225-374-1410 Fax: 225-374-1616 | |
Dr. Horace Jay Collinsworth, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 8415 Goodwood Blvd, Suite 100, Baton Rouge, LA 70806 Phone: 225-765-5633 Fax: 225-765-5634 | |
Myriam Aracelis Ortiz-de Jesus', MD Pediatrics Medicare: Medicare Enrolled Practice Location: 11424 Sullivan Rd, Suite B1, Baton Rouge, LA 70818 Phone: 225-761-5200 |